Raptor Pharma (RPTP) Tops Q2 EPS by 2c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Raptor Pharmaceutical Corp. Reports Second Quarter 2016 Financial Results
August 4, 2016 4:08 PM EDTQuarterly Revenue Increased 37.3% Year-Over-Year, to $32.0 Million
Raptor Raises 2016 Global Net Revenue Guidance to $125-$135 Million
Company to Host Conference Call and Webcast Today at 4:30 p.m. EDT/1:30 p.m. PDT
NOVATO, Calif., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (NASDAQ: RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases, today announced its financial results for the second quarter of 2016 and provided an update on recent corporate developments.
... More